Viewing Study NCT00398567

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:44 AM
Ignite Modification Date: 2026-05-24 @ 11:28 AM
Study NCT ID: NCT00398567
Status: COMPLETED
Last Update Posted: 2018-07-24
First Post: 2006-11-09
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
Sponsor: Puma Biotechnology, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None HKI-272 View
None neratinib View
None trastuzumab View
None breast cancer View
None Nerlynx View
None PB-272 View
None HER2 View